Materialise (MTLS) Q1 2025: Medical Grows 19% as Software Recurring Revenue Tops 80%
Materialise’s Q1 2025 results reveal a business bifurcated by robust medical growth and ongoing headwinds in software and manufacturing. While the medical segment delivered double-digit expansion, the company’s cloud-driven software transition weighed on reported revenue, and manufacturing faced persistent macro challenges. Management’s commitment to recurring revenue and operational discipline sets a stabilization path for the second half, but near-term volatility remains pronounced.
Summary
- Medical Segment Momentum: Personalized healthcare solutions drove outsized growth, offsetting softness elsewhere.
- Software Model Shift: Recurring revenue surpassed 80%, but deferred revenue masked top-line progress.
- Manufacturing Under Pressure: Aerospace gains contrast with broader industrial demand weakness and margin strain.
Performance Analysis
Materialise posted 4% year-over-year revenue growth in Q1 2025, reaching €66.4 million, but the headline number masks divergent segment performance and mixed profitability. The medical segment delivered nearly 19% growth, now accounting for 47% of total revenue, with both software and device sales contributing. Software and manufacturing segments each saw revenues decline by about 6%, reflecting macroeconomic drag and the ongoing shift to subscription models in software.
Profitability was pressured by higher R&D investment and foreign exchange losses, resulting in a net loss of €0.5 million for the quarter. Adjusted EBIT margin contracted to 1%, and adjusted EBITDA margin fell to 9.3%. However, free cash flow remained solid at €8 million, and net cash improved by nearly €7 million, providing a buffer against near-term volatility. The company’s software deferred revenue grew by €1.9 million, and now exceeds €49 million, highlighting the underlying health of the subscription base despite reported revenue softness.
- Medical Outperformance: Personalized devices and software adoption drove high-margin growth, with strong traction in orthopedics, CMF, cardiac, and respiratory applications.
- Software Recurring Revenue Milestone: Over 80% of software revenue is now recurring, signaling maturity in the cloud transition but depressing reported top-line figures due to deferred revenue accounting.
- Manufacturing Mixed Signals: Aerospace sales grew 23% year-over-year, but industrial and automotive segments remained weak, and overall manufacturing EBITDA stayed negative, though improved sequentially.
Segment divergence and model transition are defining the current phase, with medical providing ballast as software and manufacturing adapt to new realities. Margin compression and FX volatility remain key watchpoints.
Executive Commentary
"In our medical business, we continue to see strong uptake of our personalized solutions, driven by adoption in various anatomical areas across orthopedics, CMF, cardiac, and respiratory... To boost the adoption of personalized devices even further, we are continuously improving our segmentation, planning, and design software to make it faster and more user-friendly."
Brigitte DeVette, Chief Executive Officer
"For the first time, more than 80% of our software revenue was of a recurring nature... This also reflects the continued transition to cloud and subscription-based business model. As a result of the lower top line, adjusted EBITDA in our software segment decreased to €0.6 million."
Kuhn Berges, Chief Financial Officer
Strategic Positioning
1. Medical Segment as Growth Engine
Materialise’s medical business is now the clear growth driver, with nearly one-fifth revenue expansion year-over-year. Personalized devices and advanced software for segmentation and planning—delivered via the Mimix platform, a cloud-based clinical workflow tool—are seeing strong clinical adoption. The company’s investment in specialized solutions for niche applications (e.g., CMF, structural heart, and tracheal splints for infants) is opening new addressable markets and reinforcing pricing power.
2. Software Cloud Transition Progress
The shift to recurring, cloud-based software revenue has reached an inflection point, with over 80% of segment revenue now recurring. This provides longer-term visibility and customer lock-in, but deferred revenue recognition is temporarily suppressing reported sales and margins. The launch of new products at the Rapid TCT conference, such as the 2025 Magix release and next-gen build processors, aims to reduce customer friction and expand the user base, especially in mid-market 3D printing.
3. Manufacturing Margin Challenge and Sector Focus
Manufacturing continues to face macro-driven demand headwinds, especially in industrial and automotive. However, aerospace sales surged 23%, and renewed long-term contracts signal resilience in this vertical. The company is also reassessing its defense sector involvement, aiming to leverage geopolitical shifts for future growth, but manufacturing EBITDA remains negative, highlighting the need for further operational optimization.
4. Sustainability and Operational Discipline
Materialise’s sustainability initiatives are delivering tangible results, with a 32% reduction in emissions since 2019 and improved raw material efficiency. This dual focus on “profit and planet” is increasingly integral to customer relationships and cost control, as evidenced by the latest sustainability report and operational improvements in raw materials sourcing.
5. Balance Sheet Strength and Investment Capacity
Net cash increased to €67.7 million, and free cash flow generation remains positive, even as R&D spend rises. This financial discipline provides flexibility to weather near-term volatility and invest in high-return growth initiatives, especially in medical and software.
Key Considerations
This quarter’s results highlight the company’s strategic pivot toward medical and recurring software, while manufacturing remains a work in progress. Investors should focus on the evolving revenue mix and margin trajectory as the business model transitions.
Key Considerations:
- Medical Outperformance Offsets Headwinds: Sustained double-digit growth in medical is critical to offsetting manufacturing and software volatility.
- Deferred Revenue Masks Software Progress: The shift to recurring revenue is healthy for long-term value, but creates near-term top-line pressure and complicates segment comparisons.
- Manufacturing Recovery Hinges on Sector Mix: Aerospace and potential defense expansion may provide a pathway to margin recovery, but industrial and automotive remain challenged.
- R&D Investment Drives Differentiation: Elevated R&D spend, especially in medical, is necessary to maintain innovation leadership but adds cost pressure in the short term.
- Balance Sheet Provides Downside Protection: Strong net cash and positive free cash flow support resilience and optionality for future investments or downturns.
Risks
Persistent macroeconomic and geopolitical volatility, especially in core manufacturing end-markets, could prolong demand softness and margin pressure. The software transition, while strategically sound, may continue to obscure reported revenue growth and profitability for several quarters. Foreign exchange fluctuations and potential tariff impacts on raw materials or customer demand are additional sources of uncertainty, as flagged in both management commentary and Q&A.
Forward Outlook
For Q2 2025, Materialise expects:
- Top-line revenue to be roughly flat sequentially, with continued market uncertainty.
- Margin pressure to persist, especially in manufacturing and software.
For full-year 2025, management maintained guidance:
- Consolidated revenue of €270–285 million.
- Adjusted EBIT of €6–10 million.
Management highlighted several factors that will shape the year:
- Stabilization anticipated in the second half of 2025 as macro headwinds abate.
- Medical strength and software recurring revenue to underpin long-term growth, even as near-term volatility persists.
Takeaways
Materialise’s near-term performance is defined by segment divergence, with medical providing growth ballast as software and manufacturing adapt to new realities. The company’s disciplined approach to recurring revenue and cash flow provides resilience, but margin and demand headwinds are unlikely to abate before the second half.
- Medical and Software Model Are the Growth Levers: Investors should watch for continued medical outperformance and stabilization in deferred software revenue as signals of long-term value creation.
- Manufacturing Remains a Drag for Now: Margin recovery in manufacturing will depend on sector mix and operational discipline, with aerospace and defense as potential bright spots.
- Transition Complexity Will Persist: Reported revenue and margin volatility are likely to continue through the cloud transition and as macro headwinds play out.
Conclusion
Materialise’s Q1 2025 results underscore the company’s strategic pivot toward high-growth medical and recurring software as manufacturing lags. Balance sheet strength and disciplined investment position the company to weather near-term volatility, but sustained execution in core growth areas will be critical to realizing the full value of the business model shift.
Industry Read-Through
Materialise’s results reflect a broader pattern in the additive manufacturing and 3D printing software space, where verticalized healthcare solutions and subscription models are outpacing legacy hardware and industrial demand. The shift to recurring revenue—though disruptive to reported results—signals a maturing industry structure with higher customer retention and visibility. Manufacturers with exposure to aerospace and defense may find relative resilience, while those tied to industrial and automotive must manage through a prolonged demand reset. R&D-driven differentiation and sustainability leadership are becoming table stakes for maintaining pricing power and customer loyalty in the sector.